In one of the first studies to evaluate taxanes versus anthracyclines in the neoadjuvant setting, no added clinical benefit in either overall survival (OS) or disease-free survival (DFS) for the simultaneous administration of doxorubicin and docetaxel compared to doxorubicin and cyclophosphamide was observed during a median of 119 months of follow-up. Importantly, this does not exclude the possibility of the occurrence of a smaller benefit than the study was powered to detect, according to researchers.
In this phase 3, multicentre, randomised trial involving 25 centres in the United Kingdom, Ireland, and Belgium, the long-term outcome of women with primary or locally advanced breast cancer who were randomised to receive either doxorubicin and cyclophosphamide (n=181) or doxorubicin and docetaxel (n=182) as primary chemotherapy were compared . The maximum number of cycles was 6 cycles of either doxorubicin (60 mg/m2) + cyclophosphamide (600 mg/m2) administered i...
please login to read the entire article:
You need to register to read the entire article, please do so now.
« Clinical benefit over trastuzumab for margetuximab in HER2 breast cancer Next Article
Circulating tumour DNA may help predict recurrence in patients with early triple-negative breast cancer »
Table of Contents: SABCS 2019
Screening, Detection, and Diagnosis
Phase 2 Trial Update
Phase 3 Trial Update
Long-Term Study Results
Triple-Negative Breast Cancer
HER2-Positive Breast Cancer
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.